APA (7th ed.) Citation

S, B., H, L., I, S., J, K., SR, L., S, C., . . . JY, C. (2025). Evaluation of Safety, Pharmacokinetic, and Pharmacodynamic Characteristics of a Novel Dual mGluR5/5-HT2AR Antagonist (VVZ-2471) in a Randomized, Double-Blind, First-in-Human Study. CNS drugs, 39(6), 583. https://doi.org/10.1007/s40263-025-01181-9

Chicago Style (17th ed.) Citation

S, Bae, Lee H, Song I, Kim J, Lee SR, Cho S, Yu KS, and Chung JY. "Evaluation of Safety, Pharmacokinetic, and Pharmacodynamic Characteristics of a Novel Dual MGluR5/5-HT2AR Antagonist (VVZ-2471) in a Randomized, Double-Blind, First-in-Human Study." CNS Drugs 39, no. 6 (2025): 583. https://doi.org/10.1007/s40263-025-01181-9.

MLA (9th ed.) Citation

S, Bae, et al. "Evaluation of Safety, Pharmacokinetic, and Pharmacodynamic Characteristics of a Novel Dual MGluR5/5-HT2AR Antagonist (VVZ-2471) in a Randomized, Double-Blind, First-in-Human Study." CNS Drugs, vol. 39, no. 6, 2025, p. 583, https://doi.org/10.1007/s40263-025-01181-9.